Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Cyclophosphamide 3Vincristine 2Rituximab 2Prednisone 2Etoposide 2Doxorubicin 2pevonedistat 1iratumumab 1fludarabine phosphate 1fludarabine 1Whole-Body Irradiation 1Pentetic Acid 1N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine 1Minocycline 1Mannose-Binding Lectin 1Heparin 1Filgrastim 1EPOCH protocol 1Drug Therapy 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Dendritic Cell Sarcoma, Interdigitating × iratumumab × Clear all
NCT00298467 2010-04-26

MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma

Bristol-Myers Squibb

Phase 2 Withdrawn
45 enrolled
DermatologicLymphoidSarcoma

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Primary Cutaneous Anaplastic Large Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡